Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 ...

Cantor Fitzgerald reissued their overweight rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research ...

It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...

Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the ...

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 ...

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago. These figures ...

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...

ACADIA Pharmaceuticals is headquartered in San Diego, CA. The company has two products on the market. The first is its flagship drug Nuplazid which was approved in 2016 and remains the only ...

Orphazyme later sold the drug’s rights to KemPharma, which rebranded it as Zevra. According to GlobalData’s Pharma Intelligence Center, Miplyffa is forecast to generate $273m in global sales ...

Acadia Pharmaceuticals and PTC Therapeutics last year struck deals to sell vouchers for $150 million apiece. Zevra, a Celebration, Fla., rare-disease company, said it will use the sale proceeds to ...

CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...

Zevra Therapeutics announces a $150 million sale of its Rare Pediatric Disease Priority Review Voucher to enhance its capital. Zevra Therapeutics, Inc. has announced the sale of its Rare Pediatric ...